Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan ab - fentanyl - depotplastre - 100 mikrogram/time

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan ab - fentanyl - depotplastre - 25 mikrogram/time

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan ab - fentanyl - depotplastre - 50 mikrogram/time

Eiropas Savienība - dāņu - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiske midler - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Eiropas Savienība - dāņu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - antitrombotiske midler - prasugrel mylan, co gives sammen med acetylsalicylsyre (asa), er indiceret til forebyggelse af atherothrombotic begivenheder i voksne patienter med akut koronar syndrom (jeg. ustabil angina pectoris, non-st-segment elevation myocardial infarction [ua/nstemi] eller st-segment elevation myocardial infarction [stemi]), der gennemgår primær eller forsinket perkutan koronar intervention (pci).

Eiropas Savienība - dāņu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - carcinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er angivet som monoterapi til behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke‑småcellet lungekræft (nsclc) med aktiverende mutationer af egfr‑tk.

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

mylan ab - fentanyl - depotplastre - 12 mikrogram/time

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - clarithromycin - filmovertrukne tabletter - 250 mg

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

hameln pharma gmbh - clarithromycinlactobionat - pulver til koncentrat til infusionsvæske, opløsning - 500 mg

Dānija - dāņu - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - clarithromycin - filmovertrukne tabletter - 500 mg